- Home
- NPCE vs ORIC Comparison
NPCE vs ORIC Comparison
Compare NPCE & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCE
- ORIC
- Stock Information
- Founded
- NPCE 1997
- ORIC 2014
- Country
- NPCE United States
- ORIC United States
- Employees
- NPCE N/A
- ORIC N/A
- Industry
- NPCE Medical Specialities
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- NPCE Health Care
- ORIC Health Care
- Exchange
- NPCE Nasdaq
- ORIC Nasdaq
- Market Cap
- NPCE 424.1M
- ORIC 362.9M
- IPO Year
- NPCE 2021
- ORIC 2020
- Fundamental
- Price
- NPCE $10.39
- ORIC $10.50
- Analyst Decision
- NPCE Buy
- ORIC Strong Buy
- Analyst Count
- NPCE 7
- ORIC 8
- Target Price
- NPCE $15.14
- ORIC $18.83
- AVG Volume (30 Days)
- NPCE 412.6K
- ORIC 1.1M
- Earning Date
- NPCE 08-12-2025
- ORIC 08-11-2025
- Dividend Yield
- NPCE N/A
- ORIC N/A
- EPS Growth
- NPCE N/A
- ORIC N/A
- EPS
- NPCE N/A
- ORIC N/A
- Revenue
- NPCE $84,306,000.00
- ORIC N/A
- Revenue This Year
- NPCE $21.00
- ORIC N/A
- Revenue Next Year
- NPCE $11.81
- ORIC N/A
- P/E Ratio
- NPCE N/A
- ORIC N/A
- Revenue Growth
- NPCE 22.05
- ORIC N/A
- 52 Week Low
- NPCE $5.45
- ORIC $3.90
- 52 Week High
- NPCE $18.98
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- NPCE 36.54
- ORIC 70.83
- Support Level
- NPCE $10.10
- ORIC $9.80
- Resistance Level
- NPCE $11.53
- ORIC $11.19
- Average True Range (ATR)
- NPCE 0.66
- ORIC 0.61
- MACD
- NPCE -0.00
- ORIC -0.04
- Stochastic Oscillator
- NPCE 28.15
- ORIC 81.20
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.